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In-peptide synthesis of di-oxazolidinone and
dehydroamino acid–oxazolidinone motifs as β-turn
inducers†
Rossella De Marco, Arianna Greco, Sebastiano Rupiani, Alessandra Tolomelli,
Claudia Tomasini, Silvia Pieraccini and Luca Gentilucci*
Small and easy-to-do mimetics of β-turns are of great interest to interfere with protein–protein recog-
nition events mediated by β-turn recognition motifs. We propose a straightforward procedure for con-
straining the conformation of tetrapeptides lacking a pre-formed scaffold. According to the
stereochemistry array, N-Ts tetrapeptides including Thr or PhSer (phenylserine) at the positions 2 or
3 gave rise in a single step to the sequences Oxd2-Oxd3 or ΔAbu2-Oxd3 (Oxd, oxazolidin-2-one; ΔAbu,
2,3-dehydro-2-aminobutyric). These pseudo-Pro residues displayed highly constrained ϕ, ψ, and χ dihedral
angles, and induced clear β-turns or inverse turns of type I or II, as determined by extensive spectroscopic
and computational analyses.
Introduction
Interactions between proteins (PPI) are important for the
majority of biological functions and cellular signaling.1 Sys-
tematic studies have revealed that there is typically a small
cluster of residues at the interface of the proteins that contrib-
utes the majority of the recognition or binding affinity. Very
often, these key regions adopt well defined turn structures.2 As
a consequence, small molecules mimicking the 3D features of
the turn regions can find applications as therapeutic agents.
The β-turn occurs where the polypeptide backbone reverses
direction, and consists of four amino acid residues i to i + 3 in
which the distance between Cαi and Cαi + 3 is about 7 Å;
according to the dihedral angles ϕ and ψ of the residues i + 1
and i + 2, the turns are classified in different types.
Small mimetics of β-turns, such as the privileged structures
benzodiazepines, Freidinger lactams, internal or external
bicyclic dipeptide mimetics, spirocyclic dipeptides, etc., have
been extensively investigated and utilized to discover
compounds that can mimic or disrupt β-turn-mediated recog-
nition events.3
However, the preparation of the scaffolds and their incor-
poration in the sequence may require multi-step procedures,
resulting in low overall yields. Besides, most synthetic
methods lack flexibility and are therefore not suited to intro-
duce diversity.3 As a consequence, the development of a high
yielding, single step procedure for the introduction of a confor-
mational constraint that forces the peptide to adopt a β-turn is
currently of considerable interest.
In this work we report a straightforward procedure for con-
straining the conformation of tetrapeptides lacking a pre-
formed scaffold. The resulting β-turn mimetics include 2-oxo-
1,3-oxazolidine-4-carboxylate rings (or oxazolidin-2-one, in
short: Oxd), that we recently proposed as constrained pseudo-
Pro residues.4
Pro strongly impacts the structural and conformational pro-
perties of peptide and protein backbones and their molecular
recognition.5 It does not have a hydrogen on the amide group
and therefore cannot act as a H-bond donor. The cyclic struc-
ture forces the ϕ angle to about −65°, therefore Pro is known
as a classical breaker of both the α-helical and β-sheet struc-
tures in proteins and peptides, while it promotes the for-
mation of β-turns.2,6
Besides, due to the small free enthalpy difference between
the cis and trans Xaa-Pro bond isomers of 2.0 kJ mol−1 (com-
pared to 10.0 kJ mol−1 for other peptide bonds), there is a rela-
tively high intrinsic probability of 30% cis conformation at r.t.7
Interestingly, the cis–trans interconversion of X-Pro is one of
the rate-determining steps in protein folding.8
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c in different solvents; amide NH FT-IR of 2d, and 3b; NH chemical shift of 2a
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In order to understand the relationship between peptide
bond geometry and bioactivity, many synthetic Pro analogues
have been developed that provide restrictions of the Xaa-Pro
conformation. In general, the modifications consist in ring
substitutions with alkyl and aromatic groups, incorporation of
heteroatoms, or the expansion or contraction of the five-mem-
bered ring.9
To take advantage of the conformational bias exerted by the
Oxd pseudo-Pro, we planned to synthesize diastereomeric
N-sulfonyl tetrapeptides containing two consecutive Oxd rings,
as β-turn inducers. According to the stereochemistry array of
the amino acids, the reaction of two β-hydroxy α-amino acids
(Thr or threo-phenylserine, PhSer) already present within the
sequences at the positions 2 and 3, with bis(succinimidyl)car-
bonate (DSC), afforded two consecutive Oxd or a 2,3-dehydro-
2-aminobutyric acid (ΔAbu) in 2 and a Oxd in 3. These combi-
nations resulted in highly constrained extended or folded
structures, in particular turns or inverse turns of type I and II,
and are especially interesting because they can control not
only the ϕ and ψ dihedral angles of the backbone but also the
χ angles of the side chains.
Peptides containing Oxd rings constitute an infrequent but
remarkable class of peptidomimetics. They have found some
applications in medicinal chemistry,10 in the construction of
foldamers11 or as self-assembling scaffolds forming nano-
structures.12 Also the compounds with the ΔAbu-Oxd sequence
are of some interest, since they contain two distinct secondary
structure-forming elements. The dehydroamino acids are well
known β-turn inducers; for instance, sequential placement of




Synthesis of tetrapeptides containing di-Oxd and ΔAbu-Oxd
Very recently, we reported the synthesis of Oxd rings directly
within peptide sequences, by treatment of N-arylsulfonyl pep-
tides containing L- or D-configured Ser with DSC and a catalytic
amount of a base, in solution or in the solid phase (Scheme 1,
path a).4
Apparently, the reaction was due to the presence of the
N-sulfonyl group; indeed, the reaction of the corresponding
Fmoc- or Boc-peptides under the same conditions with car-
bonates or dicarbonates gave elimination to dehydro-
alanine (ΔAla), as reported in the literature (Scheme 1,
path b).13
Interestingly, peptides having the sulfonyl group directly
connected to the Ser, or separated by one or two amino acids,
gave similar results (Scheme 1, Xaa = 0, 1, or 2 residues).4 This
observation prompted us to perform in a single step the simul-
taneous cyclization of sulfonyl-oligopeptides containing two
consecutive ring-forming residues, to afford highly rigid
structures.
Accordingly, we prepared a series of diastereomeric tetra-
peptides containing two Thr residues, or Thr and threo-PhSer,
at the positions 2 and 3, and we reacted the tetrapeptides
(Scheme 2) with a moderate excess of DSC and a catalytic
amount of diisopropylethylamine (DIPEA).
The preparation of the N-tosyl tetrapeptides 1a–g was con-
ducted by coupling the amino acids under MW irradiation,
using a microwave oven specifically designed for organic syn-
thesis,14 with HBTU/HOBt as activating agents (Experimental
section, Table 3). N-Tosyl (Ts)-Ala was prepared as described in
the literature;15 L- and D-threo-PhSer were obtained via optical
resolution of the racemate,16 since the resolution by enzymatic
hydrolysis17 gave poor results.
The reaction of Ts-Ala-Thr-Thr-PheOMe (1a) with 2.2 equiv.
of DSC in 3 : 1 DCM–DMF and in the presence of 0.1 equiv. of
DIPEA (Scheme 2, entry 1) provided the corresponding di-Oxd-
containing Ts-Ala-Oxd-Oxd-PheOMe (2a) in excellent yield after
isolation by flash chromatography (Table 1).
On the other hand, the reaction of Ts-Ala-D-Thr-Thr-
PheOMe (1b), under the same reaction conditions, gave exclu-
sively a tetrapeptide containing ΔAbu at position 2, Ts-Ala-
ΔAbu-Oxd-PheOMe (3b), while the tetrapeptide containing two
Oxd (2b) was observed only in trace amounts (Scheme 2, and
Table 1, entry 2).
Scheme 2 Reactions of the sulfonyl-peptides 1a–e, containing L- or D-Thr at
positions 2 and 3, and of 1f, g containing L-Thr at 2 and threo L- or D-PhSer at 3,
respectively. (a) DSC, cat. DIPEA.
Scheme 1 Different reactivity of the N-carbamate and N-sulfonyl oligo-
peptides. (a) DSC, cat. base (B:).
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The reaction of Ts-Ala-Thr-D-Thr-PheOMe (1c) under the
same conditions gave a 74 : 26 mixture of Ts-Ala-Oxd-D-Oxd-
PheOMe (2c) and Ts-Ala-ΔAbu-D-Oxd-PheOMe (3c) (entry 3).
The reaction outcome changed upon varying the solvent uti-
lized; in pure DCM the yield of 2c increased to 85% (entry 4),
while in DMF the reaction afforded mainly 3c, with a 78%
yield (entry 5).
The tetrapeptide Ts-Ala-Thr-D-Thr-D-PheOMe (1d) exclu-
sively gave Ts-Ala-Oxd-D-Oxd-D-PheOMe (2d) (entry 6), while Ts-
Ala-D-Thr-Thr-D-PheOMe (1e) failed to give either 2 or 3 in sig-
nificant amounts (entry 7) under a variety of reaction con-
ditions (not shown).
Finally, the reaction was repeated with the sequences Ts-
Ala-Thr-PhSer-PheOMe (1f ) or Ts-Ala-Thr-D-PhSer-PheOMe
(1g), which gave the di-Oxd compounds 2f and 2g in very satis-
factory yields (entries 8 and 9). These peptides include a 2-oxo-
5-phenyloxazolidine-4-carboxylate residue at position 3, which
might effectively represent a constrained Phe mimetic, with
fixed ϕ, ψ and χ dihedral angles (Table S7†).
This result suggests the opportunity to develop analogues
of proteinogenic or unusual amino acids, carrying the side
chain at the position 5 of the Oxd ring. Indeed, the literature
reports many procedures for the stereocontrolled preparation
of a variety of β-hydroxy α-amino acids.18 Nevertheless, the syn-
thesis of Oxds functionalized with different side chains is
beyond the scope of this work, which primarily addresses the
synthesis of model tetrapeptides and investigation of the sec-
ondary structures.
Epimerization during the reactions was excluded on the
basis of the comparison of the NMR and HPLC analyses of the
compounds, including the HPLC analysis on a chiral station-
ary phase (see General methods).
From the comparison of the results (entries 1–9) it
appeared that the stereochemistry array exerted a major bias in
determining the cyclization versus the elimination at position
2. Homochiral sequences at positions 1 and 2 tended to give
exclusively or predominantly the di-Oxd compounds, as
observed for 1a, 1c, and 1d. On the contrary, the peptide 1e
containing the sequence L-Ala-D-Thr failed to give 2 or 3 in sig-
nificant amounts, and 1b solely afforded the ΔAbu-Oxd
sequence. The diastereomeric peptides 1f, 1g containing PhSer
behaved in a similar way to the corresponding peptides 1a and
1c (the formation of 3g was observed only in trace amounts in
different solvents).
The proposed reaction mechanism of Scheme 1, path a,
postulates that for n = 1 or 2, as occurring for the compounds
1a–g, the electron-poor aromatic ring of the arylsulfonylamido
group might effectively stabilize the anionic intermediate A by
π-stacking interaction (ESI†), thus driving formation of the Oxd
ring. Possibly, the diastereoisomer 1b adopted in solution a
conformation which allowed promoting the cyclization at posi-
tion 3, but not at 2, therefore giving elimination, as expected
on the basis of the literature. For 1c, the different results
observed for the entries 3 to 5 could be attributed to a prefer-
ence for different conformations in the different solvents. As
for 1e, showing alternating absolute stereochemistry, it
appeared that the compound was unable to achieve cyclization
either at 2 or 3; the compound did not eliminate to a signifi-
cant extent either, as observed by treatment with different
bases in different solvents at r.t. or under heating.
The mild cleavage of the arylsulfonyl group19 was discussed
previously.4,20 The tosyl group was removed in good yield with
iodotrimethylsilane,21 while the treatment with SmI2–pyrroli-
dine–water22 was less efficient.
Conformational analyses of the di-Oxd and ΔAbu-Oxd peptides
To investigate the conformational bias exerted by the two con-
secutive L- or D-configured Oxd, or ΔAbu and L- or D-Oxd resi-
dues at positions 2 and 3, on the overall structure of the
peptides, we analyzed the model compounds 2a, 2c, 2d, and
3b, 3c, by FT-IR and NMR spectroscopy.
FT-IR spectroscopy was utilized to analyze the amide N–H
stretching regions; generally, non H-bonded amide protons
show a peak above 3400 cm−1, while H-bonded amide NH
bonds exhibit a peak below 3400 cm−1.23
The FT-IR absorption spectrum of 2d only showed a strong
band above 3400 cm−1 (ESI, Fig. S1†). The spectra of 2a, 2c, 3b,
and 3c (ESI, Fig. S1†) showed a major peak at about
3400 cm−1, and a second peak at about 3340 cm−1. The latter
became predominant in 3c, suggestive of a significant popu-
lation of H-bonded conformations in equilibrium with non-
Table 1 Synthesis of the constrained peptidomimetics 2 or 3 from the stereoisomers 1
Entry 1 Ala1 Thr2 Xaa3, R Phe4 Solventa 2b (%) 3b (%)
1 a L L L Me L DCM–DMF 87 tr.
2 b L D L Me L DCM–DMF — 90
3 c L L D Me L DCM–DMF 67 23
4 c ” ” ” Me ” DCM 85 9
5 c ” ” ” Me ” DMF 5 78
6 d L L D Me D DCM–DMF 90 —
7 e L D L Me D DCM and/or DMF tr.c tr.c
8 f L L L Ph L DCM–DMF 92 —
9 g L L D Ph L DCM–DMF 93 tr.
a All compounds 1a–g were tested in different solvent mixtures (3 : 1 DCM–DMF, DCM, DMF); with the exception of entries 3–5, the reaction
outcomes were practically unaffected, therefore these results are not shown. bDetermined after purification by flash chromatography over silica
gel; tr. = traces. c The rest being the reagent.
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bonded structures. The spectrum of 3c dissolved in DCM is
reported in Fig. 1.
The 1H-NMR experiments were done at 400 MHz in CDCl3
or in 8 : 2 DMSO-d6–H2O. 2D gCOSY experiments were utilized
for the unambiguous assignment of the resonances. In each
solvent, all spectra showed a single set of sharp resonances,
consistent with conformational homogeneity or a fast equili-
brium between slightly different conformers. For most com-
pounds, the 1H-NMR resonances showed modest variations of
the chemical shifts in the two solvents (Table S1†) suggesting
that the peptidomimetic sequences were conformationally
stable; exceptions are highlighted in Table S1.†
It has been shown that the Oxd confers on the preceding
amide bond an exclusive trans conformation.11 The 1H-NMR
analyses of all of the compounds showed a significantly down-
field position of the Hα proton of the residues preceding the
Oxd rings (ESI, Table S1†). For instance, the resonances of
AlaHα in Ts-Ala-Thr-Thr-PheOMe (1a) and Ts-Ala-ΔAbu-L-(5′-
Me-Oxd)-PheOMe (3b) appeared at about 3.9 and 3.8 ppm
(CDCl3), respectively, while in Ts-Ala-(5′-Me-Oxd
2)-(5′-Me-Oxd3)-
PheOMe (2a) AlaHα was at about 5.2 ppm. On the other hand,
in the same compound 2a, Oxd3H4 was at 4.2 ppm, while
Oxd2H4 was at about 5.3 ppm, for the deshielding effect of
Oxd3CvO. These observations were compatible with a non-
conventional, CH⋯OvC intramolecular H-bond,24 confirming
the trans conformation of the amide bond between the Oxd
and the preceding, deshielded residue.
The occurrence of intramolecular H-bonds in 2a, 2c, 2d, 3b,
and 3c, was evaluated by analyzing the variation of the NH
proton chemical shifts upon addition of increasing percen-
tages of DMSO-d6 to 2 mM solutions of the compounds in
CDCl3. As representative example, the titration curves of 3c are
shown in Fig. 2. The titration of 2a gave no evidence of
H-bonds involving PheNH nor AlaNH, since these signals exhibi-
ted a considerable downfield shift;25 2c, 2d gave similar results
(ESI†). On the contrary, the titration of 3c (Fig. 2) and 3b (ESI†)
revealed that PheNH, but not AlaNH nor ΔAbuNH, was much
less sensitive, therefore less accessible, accounting for a
H-bonded structure.
Variable temperature (VT)-1H-NMR experiments in CDCl3
and 8 : 2 DMSO-d6–H2O were also utilized to deduce the pres-
ence of intramolecular H-bonds (Table 2). For almost all com-
pounds, the comparatively lower VT-1H-NMR Δδ/Δt parameters
of PheNH with respect to AlaNH (and ΔAbuNH) were sugges-
tive of a moderate preference for conformations having PheNH
involved in a H-bond (|Δδ/Δt| < or close to 2.5 ppb K−1).23,26
The only exception was observed for 2d in CDCl3, since the Δδ/
Δt (ppb K−1) of AlaNH was lower than that of PheNH (−1.7
and −2.7, respectively).
From the comparison of the results above discussed for the
Oxd–Oxd compounds (2), it appeared that the possible exist-
ence or not of H-bonds was differently supported by the
methods employed. Reasonably, the inconsistencies reflected
the existence of equilibria between H-bonded and non-H-
bonded structures. As for the ΔAbu-Oxd compounds (3), all of
the evidence was highly coherent in support of a H-bonded
PheNH.
To determine the preferred conformations in solution and
their dynamic behaviours, the compounds were analyzed by
2D-ROESY in 8 : 2 DMSO-d6–H2O and molecular dynamics
(MD) simulations. DMSO-d6 or DMSO-d6–H2O mixtures have
been recommended by several authors as biomimetic media.27
Structures consistent with the spectroscopic analyses were
obtained by MD using the distances derived from ROESY as
constraints. The intensities of the ROESY cross-peaks were
ranked to infer the distances (Tables S2–6, ESI†). The ω bonds
were set at 180°, since the absence of Hαi-Hα(i + 1) cross-peaks
excluded cis peptide bonds. Simulations were conducted in a
box of explicit water molecules. Random structures were gener-
ated by unrestrained high-temperature MD; the structures were
subjected to high-temperature restrained MD with a scaled
force field, followed by a simulation with full restraints.
Fig. 2 Variation of NH proton chemical shift (ppm) of 3c as a function of
increasing percentages of DMSO-d6 to the CDCl3 solution (v/v).
Table 2 Δδ/Δt values (ppb K−1) for the amide protons of 2a, 2c, 2d, and 3b,
3c, in CDCl3 and 8 : 2 DMSO-d6–H2O; solvents: S1 = CDCl3; S2 = 8 : 2 DMSO-d6–
H2O; amino acid stereochemistry has been omitted
Compd Solvent Ala1NH ΔAbu2NH Phe4NH
2a S1 −2.7 — −2.4
S2 −6.1 — −3.9
3b S1 −13.5 −8.0 −3.8
S2 −5.0 −7.2 −4.1
2c S1 −2.3 — −1.2
S2 −6.3 — −3.8
3c S1 −9.0 −4.4 −4.0
S2 −6.5 −7.0 −4.1
2d S1 −1.7 — −2.7
S2 −6.0 — −4.2
Fig. 1 Amide NH stretching regions of the IR absorption spectra for samples of
tetrapeptide 3c (3 mM in DCM, r.t.).
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Finally, the system was gradually cooled, and the structures
were minimized with the AMBER force field.28 The results
were clustered by the RMSD analysis of the backbone atoms.
For Ts-Ala-(5′-Me-Oxd)-(5′-Me-Oxd)-PheOMe (2a), the analy-
sis gave two clusters comprising altogether more than 90%
of the structures. For each cluster, the representative geome-
tries A and B with the lowest internal energy were selected and
analyzed (Fig. 3). The occurrence of these two different
structures, which differ almost exclusively by the opposite
orientation of the Phe residue, reflected the observation
of contradictory cross-peaks: the cross-peaks PheNH-Oxd3H4
and PheNH-Oxd3H5 accounted for the conformation A,
while the cross peak PheNH-Oxd2H5 was coherent with
B. Possibly, the two structures represented conformers in fast
equilibrium.
To investigate the dynamic behaviour of 2a (A) and (B),
unrestrained MD were performed for 10 ns in a box of stan-
dard TIP3P water molecules. The simulations showed the con-
version of one conformation into the other. The analyses of
the trajectories of the conformer (A) revealed very few struc-
tures compatible with a γ-turn centered on Oxd3 with an expli-
cit H-bond between PheNH and Oxd2CvO, while (B) gave no
evidence of secondary structures.
For Ts-Ala-(5′-Me-Oxd)-D-(5′-Me-Oxd)-PheOMe (2c) and Ts-
Ala-(5′-Me-Oxd)-(5′-Me-Oxd)-D-PheOMe (2d), the analyses gave
one major cluster each comprising about 80% of the struc-
tures. For each compound’s cluster, the representative geome-
tries with the lowest internal energy are shown in Fig. 3. These
structures 2c (C) and 2d are compatible with a well-defined
type II β-turn secondary structure (Table S7†). The structures
2c (C) and 2d were analyzed by unrestrained MD; besides
the different random conformations, the analysis of the
trajectories of 2c (C), but not of 2d, revealed an explicit H-
bond between PheNH and the AlaCvO, as shown in 2c (D),
Fig. 3.
The conformational analyses of the peptides 3b, 3c contain-
ing in their sequences ΔAbu2 and L- or D-Oxd3, respectively,
gave one cluster each, comprising the large majority of the
structures; the representative geometries are shown in Fig. 4.
Fig. 3 Top. Representative low-energy structures of 2a (A and B), 2c (C), and
2d consistent with ROESY analysis, calculated by restrained MD; low energy
structure of 2c (D) calculated by unrestrained MD. All structures determined in a
30 × 30 × 30 Å box of standard TIP3P water molecules. Backbones and Oxd are
rendered in balls and cylinders, the rest in sticks. The peptide bonds connecting
Oxd2-Oxd3 are shown horizontally and perpendicularly with respect to the
viewer. Bottom. Sketches of the extended structure of 2a (A), and of the folded
2c (D) and 2d.
Fig. 4 Top. Representative low-energy structures of 3b and 3c (E) consistent
with ROESY analysis, calculated by restrained MD; low energy structure of 3c (F)
calculated by unrestrained MD. All structures determined in a 30 × 30 × 30 Å
box of standard TIP3P water molecules. Backbones and Oxd are rendered in
balls and cylinders, the rest in sticks. The peptide bonds connecting ΔAbu2-Oxd3
are shown horizontally and perpendicularly with respect to the viewer. Bottom.
Sketches of the folded structures 3b and 3c (E).
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The calculated geometry of ΔAbu closely matched that of de-
hydroamino acids reported in the literature.13,29
The structure 3b, stabilized by an explicit H-bond between
AlaCvO and PheNH, was compatible with a type I β-turn. The
structure of 3c (E) nicely reproduced an inverse type I β-turn
(Table S7†), and showed a H-bond between AlaCvO and
PheNH. The unrestrained MD simulations also revealed a ten-
dency for structures characterized by a H-bond between
PheCvO and AlaNH, such as the representative 3c (F), Fig. 4.
To further confirm the presence of folded structures, we
used Electronic Circular Dichroism (CD) spectroscopy. Spectra
of model peptides 2a, 2d, and 3b, were recorded both in
dichloromethane and in methanol.
The spectra in dichloromethane (Fig. 5) showed a negative
band centered at about 230 nm, less intense for 2a. These
spectral features could be indicative of a significant population
of bent conformers, in particular in the case of 2d and 3b. In
fact, a negative nπ* ECD band near 225 nm is generally
observed in the presence of β-turn structures (I or II type).23,30
The observed different intensities of ECD signals were in
agreement with ROESY and MD data which evidenced homo-
geneous conformations for 2d and 3b.
By moving from dichloromethane to methanol, intensities
of the negative ECD bands slightly reduced for all compounds
(see ESI, Fig. S3†). This spectral behavior could be ascribed to
a dependence of the conformer population on the polarity
and/or the competitive nature of the solvent.
Taken together, all of the experimental evidence supports
that the peptides 3 containing the ΔAbu at the position 2
formed highly stable type I β-turns reinforced by H-bonds,
normal or inverse depending on the stereochemistry of the
Oxd3. This result is particularly gratifying, since the formation
of the ΔAbu-Oxd motif was somewhat unpredictable.
On the other hand, the data of the peptides 2 collected by
ROESY/MD analyses confirmed a certain flexibility of the Phe4
residue. This observation could explain the discrepancies in
the determination of H-bonds by IR, VT-NMR, and NMR titra-
tion experiments. Nevertheless, the results highlighted the
rigidity of the Ala-Oxd-Oxd portions; the rotation of the Ala
and the two Oxd rings with respect to each other was not
observed during the unrestrained MD simulations. The confor-
mational homogeneity was correlated to the strong preference
for all-trans conformations stabilized by the weak interactions
between the Oxd carbonyls and the Hα protons of the preced-
ing residues.
In particular, the heterochiral Oxd2-D-Oxd3 scaffold induced
a stable and well defined type II β-turn, albeit the H-bond
between the residues i − i + 3 was relatively loose. This ability
to promote folded structures makes sense, and is consistent
with the observations on previously described Oxd-pep-
tides.11,12 The oxazolidin-2-one ring can be regarded as a
pseudo-Pro; it is well known that heterochiral linear oligopep-
tides including a Pro show higher propensity to fold compared
to the homochiral sequences.23,26
Conclusions
In this paper we reported a straightforward, one-step pro-
cedure for constraining a peptide backbone without the need
for a pre-formed scaffold. The cyclization of two consecutive
β-hydroxy amino acid residues (L/D-Thr or threo-L/D-PhSer)
embedded in N-arylsulfonyl tetrapeptide sequences afforded
in excellent yields the peptides containing Oxd2-L/D-Oxd3 (2) or
ΔAbu2-L/D-Oxd3 (3), according to the stereochemistry array of
the precursors.
Conformational analyses of the model peptides revealed
that the homochiral Oxd2-Oxd3 dipeptidomimetic induced an
extended disposition of the backbone. The heterochiral
sequences exerted a strong conformational control, giving rise
to type II β-turns. The unrestrained MD simulations confirmed
the rigidity of the conformations, since the rotation of the two
Oxd rings with respect to each other was not observed during
the simulations. On the other hand, the sequence ΔAbu2-Oxd3
induced highly stable β-turns of type I, stabilized by clear
H-bonds.
For their ability to control the ϕ and ψ dihedral angles of
the backbone as well as the χ dihedral angles of side chains,
peptide mimetics based on the structures of the model pep-
tides 2 and 3 might find applications in medicinal chemistry
as 3D rigid scaffolds, in the field of foldamers, or as self-
assembling scaffolds to form nanostructures.
Experimental
General methods
Unless stated otherwise, standard chemicals were obtained
from commercial sources and used without further purifi-
cation. Flash chromatography was performed on silica gel
(230–400 mesh), using mixtures of distilled solvents. Analytical
RP-HPLC was performed on an ODS column (4.6 μm particle
size, 100 Å pore diameter, 250 μm, DAD 210 nm, from a 9 : 1
H2O–CH3CN to a 2 : 8 H2O–CH3CN in 20 min) at a flow rate of
1.0 mL min−1, followed by 10 min at the same composition.
Semi-preparative RP-HPLC was performed on a C18 column
(7 μm particle size, 21.2 mm × 150 mm, from 8 : 2 H2O–CH3CN
to 100% CH3CN in 10 min) at a flow rate of 12 mL min
−1.
Purities were assessed by analytical RP-HPLC under the above
Fig. 5 ECD spectra recorded in dichloromethane at room temperature (2a
dotted line, 3b dashed line, 2d full line).
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reported conditions and elemental analysis. Chiral HPLC ana-
lysis was performed on a CHIRALPAK IC column (0.46 cm ×
25 cm), 1 : 1 n-hexane–2-propanol, at 0.8 mL min−1. Semi-pre-
parative and analytical RP-HPLC of the peptide 14 was per-
formed as reported above, with the addition of 0.1% TFA in
the mobile phase. Elemental analyses were performed using a
Thermo Flash 2000 CHNS/O analyzer. High-quality IR were
obtained at 2 cm−1 resolution using a FT-IR spectrometer and
1 mm NaCl solution cell. 1H-NMR spectra were recorded on a
Varian instrument at 400 MHz, 13C-NMR spectra at 100 MHz.
Circular Dichroism (CD) spectra were recorded on a Jasco J-710
spectropolarimeter. The synthetic procedure by MW
irradiation was performed using a microwave oven (Micro-
SYNTH Microwave Labstation for Synthesis).
Synthesis of the peptides 1a–g
A stirred solution of the N-protected amino acid in 4 : 1 DCM–
DMF (5 mL) was treated with HOBt (1.2 equiv.) and HBTU (1.2
equiv.), at r.t. and under inert atmosphere. After 5 min, the
C-protected amino acid (1.1 equiv.) and DIPEA (2.4 equiv.) were
added, and the mixture was stirred under inert atmosphere
and under MW irradiation (150 W). After 10 min, the mixture
was concentrated at reduced pressure, and the residue was
diluted with EtOAc (25 mL). The solution was washed with 0.1
M HCl (5 mL), and a saturated solution of NaHCO3 (5 mL).
The organic layer was dried over Na2SO4 and the solvent was
evaporated at reduced pressure. The crude peptides were ana-
lyzed by HPLC-MS analysis, and were used without further
purification.
The intermediate N-Boc peptides were deprotected by treat-
ment with 1 : 2 TFA–DCM (5 mL), while stirring at r.t. After
15 min, the solution was evaporated under reduced pressure,
and the treatment was repeated. The residue was suspended in
Et2O (20 mL). The peptide–TFA salts were collected by centri-
fuge, and used for the next couplings without further purifi-
cation (80–85% pure, Table 3).
Synthesis of Ts-Ala-Oxd-(5′-R-Oxd)-PheOMe (2a, c, d, f, g),
Ts-Ala-ΔAbu-(5′-Me-Oxd)-PheOMe (3b, c).
DSC (0.73 mmol) was added to a stirred solution of 1
(0.33 mmol) in the solvent mixture of Table 1 (4 mL) followed
by DIPEA (0.07 mmol) at r.t. and under inert atmosphere.
After 3 h, the solvent was removed under reduced pressure, the
residue was diluted with 0.1 M HCl (5 mL), and the mixture
was extracted three times with DCM (5 mL). The combined
organic layers were dried over sodium sulfate, filtered, and
concentrated at reduced pressure. The residue was purified by
semi-preparative RP-HPLC (see General methods), giving 2
(85–93%, see Table 1, 94–97% pure by analytical RP-HPLC) or
3 (78–90%, see Table 1, 95–98% pure by analytical RP-HPLC),
as waxy solids.
Ts-Ala-(5′-Me-Oxd2)-(5′-Me-Oxd3)-PheOMe (2a). IR (CH2Cl2)
ν: 3406, 3335, 1789, 1736, 1703, 1670 cm−1; 1H-NMR (CDCl3) δ:
1.43 (d, J = 6.8 Hz, 3H, AlaMe), 1.52 (d, J = 6.3 Hz, 6H, Oxd2Me
+ Oxd3Me), 2.43 (s, 3H, TsMe), 3.11 (dd, J = 5.5, 14.1 Hz, 1H,
PheHβ), 3.15 (dd, J = 5.4, 14.1 Hz, 1H, PheHβ), 3.77 (s, 3H,
OMe), 4.26 (d, J = 3.7 Hz, 1H, Oxd3H4), 4.58 (dq, J = 2.1, 6.3 Hz,
1H, Oxd2H5), 4.75 (dq, J = 3.7, 6.3 Hz, 1H, Oxd
3H5), 4.85 (q,
J = 7.6 Hz, 1H, PheHα), 5.22 (dq, J = 6.8, 10.4 Hz, 1H, AlaHα),
5.26 (d, J = 2.1 Hz, 1H, Oxd2H4), 5.39 (d, J = 10.4 Hz, 1H,
AlaNH), 6.28 (d, J = 7.6 Hz, 1H, PheNH), 7.04–7.11 (m, 2H,
PheArH), 7.21–7.26 (m, 3H, PheArH), 7.31 (d, J = 8.0 Hz, 2H,
TsArH), 7.75 (d, J = 8.0 Hz, 2H, TsArH); 13C-NMR (DMSO-d6) δ:
18.5, 20.5, 21.3, 21.4, 36.9, 50.1, 52.5, 54.3, 61.0, 61.6, 74.7,
76.6, 126.0, 127.2, 128.6, 128.8, 129.6, 130.1, 137.0, 138.2,
143.5, 152.0, 153.2, 167.4, 167.7, 171.7, 172.4; ES-MS (m/z)
659.3 [M + 1], calcd 659.2; Elem. Anal. for C30H34N4O11S,
calcd: C 54.70, H 5.20, N 8.51, S 4.87; found: C 54.67, H 5.17,
N 8.45, S 4.81%.
Ts-Ala-ΔAbu-(5′-Me-Oxd)-PheOMe (3b). IR (CH2Cl2) ν:
3407, 3318, 1789, 1748, 1708 cm−1; 1H-NMR (CDCl3) δ: 1.23
(d, J = 6.8 Hz, 3H, AlaMe), 1.43 (d, J = 6.0 Hz, 3H, OxdMe),
1.79 (d, J = 7.2 Hz, 3H, ΔAbuMe), 2.43 (s, 3H, TsMe), 3.03
(dd, J = 8.2, 13.8 Hz, 1H, PheHβ), 3.23 (dd, J = 5.4, 13.8 Hz,
1H, PheHβ), 3.71 (s, 3H, OMe), 3.85 (quint, J = 7.2 Hz, 1H,
AlaHα), 4.36–4.41 (m, 2H, OxdH4,5), 4.84 (q, J = 8.2 Hz, 1H,
PheHα), 5.92 (d, J = 6.8 Hz, 1H, AlaNH), 6.04 (q, J = 7.2 Hz,
1H, ΔAbuHβ), 7.14–7.22 (m, 2H, PheArH), 7.24–7.34 (m, 5H,
PheArH + TsArH), 7.64 (d, J = 8.0 Hz, 1H, PheNH), 7.77 (d,
J = 7.6 Hz, 2H, TsArH), 8.66 (s, 1H, ΔAbuNH); 13C-NMR
(DMSO-d6) δ: 12.8, 19.4, 20.3, 37.0, 51.9, 52.4, 54.1, 62.1,
75.0, 120.5, 126.9, 127.2, 128.8, 129.6, 130.1, 130.5, 134.1,
137.1, 138.7, 143.2, 151.8, 168.6, 170.8, 170.9, 171.9; ES-MS
(m/z) 615.4 [M + 1], calcd 615.2; Elem. Anal. for
C29H34N4O9S, calcd: C 56.67, H 5.58, N 9.11, S 5.22; found:
C 56.78, H 5.56, N 9.08, S 5.18%.
Ts-Ala-(5′-Me-Oxd2)-D-(5′-Me-Oxd3)-PheOMe (2c) IR (CH2Cl2)
ν 3406, 3347, 1793, 1736, 1707 cm−1; 1H-NMR (CDCl3) δ: 1.33
(d, J = 6.6 Hz, 3H, AlaMe), 1.47 (d, J = 6.2 Hz, 3H, Oxd2Me),
1.53 (d, J = 6.4 Hz, 3H, Oxd3Me), 2.42 (s, 3H, TsMe), 3.01 (dd,
J = 6.4, 14.1 Hz, 1H, PheHβ), 3.20 (dd, J = 6.4, 14.1 Hz, 1H,
PheHβ), 3.77 (s, 3H, OMe), 4.29 (d, J = 4.8 Hz, 1H, Oxd3H4),
4.53 (dq, J = 2.4, 6.4 Hz, 1H, Oxd2H5), 4.64 (quint, 1H, J = 6.2
Hz, Oxd3H5), 4.82 (q, J = 6.4 Hz, 1H, PheHα), 5.11 (dq, J = 6.8,
13.6 Hz, 1H, AlaHα), 5.24 (d, J = 2.4 Hz, 1H, Oxd2H4), 5.44 (d,
J = 10.0 Hz, 1H, AlaNH), 6.55 (d, J = 7.6 Hz, 1H, PheNH), 7.09 (d,
J = 7.2 Hz, 2H, PheArH), 7.24–7.31 (m, 5H, PheArH + TsArH),
7.73 (d, J = 7.6 Hz, 2H, TsArH); 13C-NMR (DMSO-d6) δ: 18.5,
20.4, 20.5, 21.4, 37.4, 50.3, 52.6, 53.8, 61.3, 62.0, 69.4, 70.1,
127.2, 128.4, 128.7, 129.8, 130.1, 137.4, 138.3, 143.5, 152.3,
153.3, 166.5, 167.1, 171.7, 172.0; ES-MS (m/z) 659.4 [M + 1],
Table 3 RP-HPLC and ES-MS analyses of the linear peptides 1a–f
1
ES-MS m/z
[M + 1] vs. calcd
Puritya
(%) 1




a 607.3/607.2 85 e 607.2/607.2 84
b 607.2/607.2 83 f 669.3/669.3 84
c 607.3/607.2 81 g 669.4/669.3 83
d 607.1/607.2 80
aDetermined by analytical RP-HPLC, see General methods.
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calcd 659.2; Elem. Anal. for C30H34N4O11S, calcd: C 54.70, H
5.20, N 8.51, S 4.87; found: C 54.60, H 5.14, N 8.44, S 4.81%.
Ts-Ala-ΔAbu-D-(5′-Me-Oxd)-PheOMe (3c). IR (CH2Cl2) ν:
3400, 3334, 1781, 1744, 1707 cm−1; 1H-NMR (CDCl3) δ: 1.28 (d,
J = 7.2 Hz, 3H, AlaMe), 1.54 (d, J = 6.0 Hz, 3H, OxdMe), 1.89 (d,
J = 7.2 Hz, 3H, ΔAbuMe), 2.46 (s, 3H, TsMe), 3.09 (dd, J = 9.0,
13.8 Hz, 1H, PheHβ), 3.18 (dd, J = 6.2, 13.8 Hz, 1H, PheHβ),
3.72 (s, 3H, OMe), 3.87 (m, 1H, AlaHα), 4.45 (d, J = 7.2 Hz, 1H,
OxdH4), 4.59 (quint, J = 6.5 Hz, 1H, OxdH5), 4.79 (q, J = 8.4 Hz,
1H, PheHα), 5.66 (br.d, 1H, AlaNH), 6.27 (q, J = 6.6 Hz, 1H,
ΔAbuHβ), 7.21 (d, J = 8.4, 2H, PheArH), 7.23–7.33 (m, 3H,
PheArH), 7.35 (d, J = 7.8 Hz, 2H, TsArH), 7.80 (d, J = 7.8 Hz,
2H, TsArH), 7.98 (d, J = 8.0 Hz, 1H, PheNH), 8.28 (s, 1H,
ΔAbuNH); 13C-NMR (DMSO-d6) δ: 12.8, 16.9, 21.5, 25.7, 37.8,
52.8, 54.7 56.9, 62.0, 75.2, 121.9, 126.0, 127.0, 128.7, 129.9,
132.0, 134.4, 136.3, 143.0, 154.8, 168.4, 170.8, 171.6; ES-MS
(m/z) 615.4 [M + 1], calcd 615.2; Elem. Anal. for C29H34N4O9S,
calcd: C 56.67, H 5.58, N 9.11, S 5.22; found: C 56.60, H 5.52,
N 9.02, S 5.15%.
Ts-Ala-(5′-Me-Oxd2)-D-(5′-Me-Oxd3)-D-PheOMe (2d). IR
(CH2Cl2) ν: 3409, 1776, 1747, 1707, 1608, 1420 cm
−1; 1H-NMR
(CDCl3) δ: 1.40 (d, J = 7.0 Hz, 3H, AlaMe), 1.46 (d, J = 6.0 Hz,
3H, Oxd3Me), 1.58 (d, J = 6.3 Hz, 3H, Oxd2Me), 2.44 (s, 3H,
TsMe), 3.05 (dd, J = 8.3, 13.9 Hz, 1H, PheHβ), 3.17 (dd, J = 5.3,
13.9 Hz, 1H, PheHβ), 3.74 (s, 3H, OMe), 4.29–4.37 (m, 2H,
Oxd3H4,5), 4.58 (dq, J = 3.5, 6.3 Hz, 1H, Oxd
2H5), 4.88 (ddd, J =
5.3, 8.3, 8.5 Hz, 1H, PheHα), 5.16 (dq, J = 7.0, 10.8 Hz, 1H,
AlaHα), 5.42 (d, J = 3.5 Hz, 1H, Oxd2H4), 5.61 (d, J = 10.8 Hz,
1H, AlaNH), 6.63 (d, J = 8.5 Hz, 1H, PheNH), 7.14 (d, J = 6.6 Hz,
2H, PheArH), 7.22–7.37 (m, 5H, PheArH + TsArH), 7.76 (d, J =
8.0 Hz, 2H, TsArH); 13C-NMR (CDCl3) δ: 18.9, 20.6, 20.9, 21.5,
37.9, 51.1, 52.6, 53.4, 61.1, 62.4, 74.2, 76.0, 127.2, 127.4, 128.6,
129.3, 129.7, 135.6, 136.9, 143.8, 151.1, 152.0, 165.7, 168.1,
171.4, 173.8; ES-MS (m/z) 659.3 [M + 1], calcd 659.2; Elem.
Anal. for C30H34N4O11S, calcd: C 54.70, H 5.20, N 8.51, S 4.87;
found: C 54.65, H 5.26, N 8.50, S 4.82%.
Ts-Ala-(5′-Me-Oxd2)-(5′-Ph-Oxd3)-PheOMe (2f ). IR (CH2Cl2)
ν: 3407, 3350, 1790, 1740, 1699, 1660 cm−1; 1H-NMR (CDCl3) δ:
1.41 (d, J = 7.2 Hz, 3H, AlaMe), 1.55 (d, J = 6.2 Hz, 6H,
Oxd2Me), 2.43 (s, 3H, TsMe), 3.12 (d, J = 5.6 Hz, 2H, PheHβ),
3.78 (s, 3H, OMe), 4.53 (d, J = 4.4 Hz, 1H, Oxd3H4), 4.66 (dq, J =
2.0, 6.2 Hz, 1H, Oxd2H5), 4.90 (q, J = 7.6 Hz, 1H, PheHα), 5.24
(dq, J = 7.6, 10.8 Hz, 1H, AlaHα), 5.35 (d, J = 2.0 Hz, 1H,
Oxd2H4), 5.41 (d, J = 10.8 Hz, 1H, AlaNH), 5.57 (d, J = 4.4 Hz,
1H, Oxd3H5), 6.31 (d, J = 7.7 Hz, 1H, PheNH), 7.04–7.12 (m,
2H, PheArH), 7.20–7.30 (m, 5H, PheArH + 5′-PhArH), 7.31 (d,
J = 8.0 Hz, 2H, TsArH), 7.39–7.44 (m, 3H, 5′-PhArH), 7.77 (d, J =
8.0 Hz, 2H, TsArH); 13C-NMR (CDCl3) δ: 19.5, 21.1, 21.5, 37.2,
50.6, 52.7, 53.7, 61.2, 65.8, 73.8, 79.0, 125.2, 127.3, 127.6,
129.1, 129.4, 129.5, 129.9, 130.1, 135.9, 136.6, 143.8, 151.1,
152.3, 166.1, 167.4, 173.1, 173.4; ES-MS (m/z) 721.2 [M + 1],
calcd 721.2; Elem. Anal. for C35H36N4O11S, calcd: C 58.32,
H 5.03, N 7.77, S, 4.45; found: C 58.29, H 5.09, N 7.80, S, 4.40%.
Ts-Ala-(5′-Me-Oxd2)-D-(5′-Ph-Oxd3)-PheOMe (2g). IR (CH2Cl2)
ν: 3409, 3345, 1779, 1730, 1700, 1656 cm−1; 1H-NMR (CDCl3) δ:
1.30 (d, J = 7.3 Hz, 3H, AlaMe), 1.52 (d, J = 6.4 Hz, 3H,
Oxd2Me), 2.43 (s, 3H, TsMe), 3.03 (dd, J = 7.2, 14.4 Hz, 2H,
PheHβ), 3.23 (dd, J = 6.0, 14.4 Hz, 2H, PheHβ), 3.76 (s, 3H,
OMe), 4.53–4.61 (m, 2H, Oxd2H5 + Oxd
3H4), 4.88 (q, J = 7.6 Hz,
1H, PheHα), 5.13 (dq, J = 7.6, 10.8 Hz, 1H, AlaHα), 5.29 (d, J =
2.4 Hz, 1H, Oxd2H4), 5.50–5.58 (m, 2H, AlaNH + Oxd
3H5), 6.63
(d, J = 7.7 Hz, 1H, PheNH), 7.04–7.11 (m, 2H, PheArH),
7.15–7.20 (m, 2H, 5′-PhArH), 7.20–7.25 (m, 3H, PheArH), 7.31
(d, J = 8.0 Hz, 2H, TsArH), 7.39–7.43 (m, 3H, 5′-PhArH), 7.76
(d, J = 8.0 Hz, 2H, TsArH); 13C-NMR (CDCl3) δ: 19.3, 20.6, 21.5,
37.6, 50.7, 53.3, 53.5, 60.8, 63.4, 71.8, 79.0, 125.3, 127.4, 128.7,
129.2, 129.5, 129.7, 130.1, 134.7, 135.7, 136.7, 143.6, 151.3,
152.3, 165.4, 167.0, 171.2, 173.1; ES-MS (m/z) 721.3 [M + 1],
calcd 721.2; Elem. Anal. for C35H36N4O11S, calcd: C 58.32, H
5.03, N 7.77, S, 4.45; found: C 58.22, H 5.07, N 7.71, S, 4.49%.
Conformational analysis
IR analyses. Infrared spectra were obtained at 2 cm−1 resolu-
tion using a 1 mm NaCl solution cell and a FT-IR spectrometer
(64 scans). All spectra were obtained in 3 mM solutions in dry
CH2Cl2 at 297 K. The compounds were dried in vacuo, and all
the sample preparations were performed in a inert
atmosphere.
Circular dichroism. ECD spectra were recorded from 200 to
400 nm at 25 °C. 1 mM solutions were made up in spectral
grade solvents and run in a 0.1 cm quartz cell. Data are
reported in molar ellipticity [θ] (deg cm2 dmol−1).
NMR analyses. 1H-NMR spectra were recorded at 400 MHz
in 5 mm tubes, using 0.01 M peptide at room temperature.
Solvent suppression was performed by the solvent presatura-
tion procedure implemented in Varian (PRESAT). 13C-NMR
spectra were recorded at 100 MHz. Chemical shifts are
reported as δ values. The unambiguous assignment of
1H-NMR resonances was performed by 2D gCOSY, HMBC, and
HSQC. gCOSY experiments were conducted with a proton spec-
tral width of 3103 Hz. VT-1H-NMR experiments were per-
formed over the range of 298–348 °K. 2D spectra were recorded
in the phase sensitive mode and processed using a 90°-shifted,
squared sine-bell apodization. 2D ROESY experiments were
recorded in 8 : 2 DMSO-d6–H2O, with a 250 ms mixing time
with a proton spectral width of 3088 Hz. Peaks were calibrated
on DMSO.
ROESY and molecular dynamics. Only ROESY-derived con-
straints were included in the restrained molecular dynamics.
Cross-peak intensities were classified very strong, strong,
medium, and weak, and were associated with distances of 2.2,
2.6, 3.0, and 4.5 Å, respectively. Geminal couplings and other
obvious correlations were discarded. For the absence of Hα(i, i
+ 1) ROESY cross peaks, all of the ω bonds were set at 180°
(force constant: 16 kcal mol−1 Å−2). The restrained MD simu-
lations were conducted using the AMBER force field in a 30 ×
30 × 30 Å box of standard TIP3P models of equilibrated
water.31 All water molecules with atoms that come closer than
2.3 Å to a solute atom were eliminated. A 100 ps simulation at
1200 °K was used for generating 50 random structures that
were subsequently subjected to a 50 ps restrained MD with a
50% scaled force field at the same temperature, followed by
Organic & Biomolecular Chemistry Paper

































50 ps with full restraints (distance force constant of 7 kcal
mol−1 Å−2), after which the system was cooled in 20 ps to 50 °
K. H-bond interactions were not included, nor were torsion
angle restraints. The resulting structures were minimized with
3000 cycles of steepest descent and 3000 cycles of conjugated
gradient (convergence of 0.01 kcal Å−1 mol−1). The backbones
of the structures were clustered by the RMSD analysis module
of HyperChem.32 Unrestrained MD simulation was performed
in a 30 × 30 × 30 Å box of standard TIP3P water for 10 ns at
298 °K, at constant temperature and pressure (Berendsen
scheme,33 bath relaxation constant of 0.2). For 1–4 scale
factors, van der Waals and electrostatic interactions are scaled
in AMBER to half their nominal value. The integration time
step was set to 0.1 fs.
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